Food and Drug Administration

The Hatch-Waxman Act, despite its intentions, has become a monopoly-extending machine that prioritizes pharmaceutical profits over public health. A 40th birthday is a good chance for anyone to rethink where their life is headed — and major legislation is no exception.

As 2022 ends and 2023 begins with record-breaking winter heat blanketing Europe and much of the south and north-eastern United States—68°F and humid in DC, in January!—climate change is in the air, if not on the legislative agenda. We expect that much of the hard-won climate progress in the next year will be in executive branch implementation and regulation, alongside state-level legislation and court cases.

In 2008, a deadly salmonella outbreak from contaminated peanut products killed nine and sickened over 700 people. In the aftermath, the peanut executives who poisoned people with food they knew was contaminated received decades-long prison sentences, an all-too-rare case of a corporate criminal being held responsible for the harm they caused. Contemporary public outrage also helped to fuel a push for more structural reform to the food safety regulatory system as a whole. Shortly after the outbreak, the Obama administration began whipping bipartisan congressional support for the Food Safety Modernization Act (FSMA), which sought to prevent future food safety crises by expanding and strengthening the Food and Drug Administration’s (FDA) authority over food. FSMA ultimately passed both the Senate and the House by wide margins and enjoyed broad public support when finally enacted in 2011.